- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06246409
Modernizing Instructions to Improve Treatment Participation of Subjects During Their First Radiotherapy (PEERs)
March 3, 2026 updated by: University of Florida
Daily patient participation is critical to the successful, life-saving delivery of radiotherapy.
There is very little in the literature describing the best way to prepare patients to give optimal participation.
This study aims to look at an already-prepared conversion of patient instruction materials and measure whether the improvement in clarity and specificity produces the desired changes in patient decision-making and emotional comfort.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
650
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Amy Carrao-Tackett
- Phone Number: 352-265-8826
- Email: amy.carrao-tackett@ufhealth.org
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Recruiting
- University of Florida
-
Contact:
- Amy Carrao-Tackett
- Phone Number: 352-265-8826
- Email: amy.carrao-tackett@ufhealth.org
-
Principal Investigator:
- Alexandra De Leo, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients ≥ 18 years old planning their first external beam radiotherapy
- Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures.
Exclusion Criteria:
- Have received external beam radiotherapy in the past
- External beam radiotherapy is initiated as inpatient.
- External beam radiotherapy consists of less than 3 fractions.
- Planned radiotherapy that does not employ an external beam
- Planned participation in a clinical study that prohibits participation in a second, concurrent treatment trial
- Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Arm 1: Existing patient instructions
|
Patients will be given the patient instructions currently in use prior to radiotherapy treatment.
|
|
Experimental: Arm 2: Modernized patient instructions
|
Patients will be given modernized patient instructions prior to radiotherapy treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Unintentional missed treatment days
Time Frame: 8 weeks
|
Determine the number of unintentional missed days of treatment during a course of radiotherapy
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient-reported comfort
Time Frame: 8 weeks
|
Evaluate patient-reported comfort with participation in radiotherapy.
|
8 weeks
|
|
Unplanned clinic visits
Time Frame: 8 weeks
|
Determine the average number of unplanned clinic visits during radiotherapy.
|
8 weeks
|
|
Emergency department visits
Time Frame: 8 weeks
|
Determine the average number of emergency department visits during radiotherapy.
|
8 weeks
|
|
Hospitalizations
Time Frame: 8 weeks
|
Determine the average number of hospitalizations during radiotherapy.
|
8 weeks
|
|
Rate of treatment completion
Time Frame: 8 weeks
|
Determine the rate of completion of the prescribed number of radiotherapy treatments.
|
8 weeks
|
|
Patient participation in treatment
Time Frame: 8 weeks
|
Determine the percentage of patients fully participating in their radiotherapy treatment, as assessed by Likert scale ratings given by the therapist.
Patients will be rated by the therapist on factors such as correct patient-initiated alignment of body, holding still, and following breath-hold directions.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Alexandra De Leo, MD, University of Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 24, 2024
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
January 30, 2024
First Submitted That Met QC Criteria
January 30, 2024
First Posted (Actual)
February 7, 2024
Study Record Updates
Last Update Posted (Actual)
March 4, 2026
Last Update Submitted That Met QC Criteria
March 3, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UF-CCPS-038
- IRB202401379 (Other Identifier: University of Florida)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.